A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
April 30th, 2020
6.3K views
We describe the creation of a rat model of pressure overload induced moderate remodeling and early systolic dysfunction where signal transduction pathways involved in the initiation of the remodeling process are activated. This animal model will aid in identifying molecular targets for applying early therapeutic anti-remodeling strategies for heart failure.
Overview
This study presents a rat model of pressure overload that induces moderate remodeling and early systolic dysfunction. The model is designed to activate signal transduction pathways involved in the remodeling process, aiding in the identification of molecular targets for early therapeutic strategies in heart failure.
Key Study Components
Area of Science
- Cardiovascular research
- Heart failure mechanisms
- Animal modeling
Background
- Previous models focused on severe systolic heart failure.
- Understanding cardiac remodeling is crucial for developing therapies.
- Metabolic remodeling and myocardial dysfunction are key areas of interest.
- Calcium cycling plays a significant role in cardiac function.
Purpose of Study
- To create a milder rat model for studying cardiac remodeling.
- To investigate pathways involved in the initiation of remodeling.
- To identify potential therapeutic targets for heart failure.
Methods Used
- Modification of a vascular hemoclip ligation tool for the procedure.
- Confirmation of anesthetic depth and preparation of the rat.
- Mechanical ventilation setup for the animal during the procedure.
- Monitoring of physiological responses throughout the experiment.
Main Results
- Successful induction of moderate remodeling in the rat model.
- Activation of key signal transduction pathways observed.
- Establishment of early systolic dysfunction in the model.
- Potential for identifying therapeutic targets for intervention.
Conclusions
- The rat model provides a valuable tool for studying heart failure.
- Insights gained may lead to early therapeutic strategies.
- Future research can build on this model to explore further interventions.
Frequently Asked Questions
What is the significance of this rat model?
It allows researchers to study moderate remodeling and early dysfunction in heart failure, providing insights for therapeutic strategies.
How does this model differ from previous ones?
This model is a milder version, focusing on moderate remodeling rather than severe systolic heart failure.
What pathways are being studied in this research?
The study investigates signal transduction pathways involved in cardiac remodeling and dysfunction.
What are the potential applications of this research?
The findings may help identify molecular targets for early therapeutic interventions in heart failure.
What methods are used to prepare the rat for the study?
The preparation includes anesthetic confirmation, shaving, and intubation for mechanical ventilation.
What are the expected outcomes of this study?
The study aims to establish a model that can effectively simulate early systolic dysfunction and remodeling.
Executive Industry Relevance
This rat model enables early-stage investigation of cardiac remodeling pathways, supporting target validation in heart failure drug discovery. By capturing moderate remodeling and systolic dysfunction, it provides a disease-relevant system for mechanistic de-risking of anti-remodeling therapeutics. The model aids in prioritizing targets with predictive confidence before advancing to overt heart failure phenotypes.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates signal transduction pathways involved in initiation of cardiac remodeling.
- Scientific Value: Supports functional target validation by mimicking early human systolic HF phenotypes.
- Scientific Value: Enables phenotypic screening for compounds that modulate metabolic remodeling and calcium cycling.
Screening & Assay Development
- Scientific Value: Provides standardized echocardiographic outputs for longitudinal monitoring of LV volumes and wall thickness.
- Operational Value: Enables reproducible quantification of LV diastolic (600-700 µL) and systolic (120-160 µL) volumes in MOD phenotype.
- Operational Value: Supports pressure volume loop analysis for contractility and stiffness assessment in preclinical workflows.
Translational & Preclinical Research
- Scientific Value: Aligns with human HF pathophysiology via conserved gene expression and post-translational modifications.
- Scientific Value: Facilitates biomarker discovery for early remodeling stages.
- Operational Value: Permits early therapeutic intervention testing before overt failure develops.
- Strategic Value: Reduces biological noise through phenotype confirmation via echocardiography.
Pipeline & Workflow Integration
The model fits within the discovery continuum from target identification to preclinical efficacy testing, enabling iterative pathway de-risking.
- Discovery Biology: Tests hypotheses on metabolic remodeling and calcium handling pathways.
- Screening: Delivers quantitative, echocardiography-based phenotypic readouts for compound screening.
- Analytics: Generates pressure volume loop data to assess systolic dysfunction and arterial-ventricular coupling.
- Translational Research: Bridges discovery to preclinical validation through disease-relevant remodeling signatures.
- Enterprise Reuse: Serves as a reusable platform for evaluating multiple therapeutic targets in HF.
Operational & Enterprise Impact
- Scientific Value: Increases target confidence by modeling early HF mechanisms.
- Operational Value: Standardizes phenotype characterization via echocardiography to reduce variability.
- Strategic Value: Improves go/no-go decisions by identifying targets effective in moderate remodeling.
- Portfolio Impact: Enables risk-adjusted prioritization of anti-remodeling candidates.
Implementation Considerations
- Requires expertise in rodent thoracic surgery and vascular clip placement.
- Depends on echocardiography equipment for longitudinal phenotyping.
- Necessitates cross-functional coordination between surgery, imaging, and pharmacology teams.
- Involves adaptation considerations for different rat strains or ages.
- Limited by high surgical mortality and low phenotype penetrance (~20%).
Biopharma FAQs
Why does echocardiography-based LV volume measurement matter for target validation?
Echocardiography enables non-invasive, serial quantification of left ventricular diastolic and systolic volumes, which are key phenotypic markers of moderate remodeling. These measurements (600-700 µL diastolic, 120-160 µL systolic) allow researchers to confirm phenotype consistency and assess therapeutic impact on cardiac dimensions. Reliable LV volume tracking supports go/no-go decisions in target validation workflows.
How does ascending aortic banding with a 2 mm² clip enable independent variable isolation in the discovery pipeline?
The fixed stenosis created by the 2 mm² vascular clip establishes a consistent pressure overload stimulus, isolating aortic pressure as the independent variable driving remodeling. This standardization reduces variability between animals and ensures that observed phenotypic changes are attributable to the pressure overload intervention. Such control is essential for attributing molecular changes to the experimental condition in target validation studies.
What quantitative dependent variable measurements enable mechanistic de-risking of anti-remodeling targets?
Dependent variables include left ventricular wall thickness, end-diastolic and end-systolic volumes, and pressure volume loop-derived metrics such as contractility and arterial stiffness. These echocardiography and catheter-based readouts quantify structural and functional changes in the heart, enabling assessment of target engagement on remodeling pathways. Quantitative tracking of these variables supports prediction of clinical translatability.
Why do replication requirements matter for cross-functional collaboration in this model?
Due to the high mortality and low penetrance (~20%) of the MOD phenotype, replication is necessary to distinguish true biological effects from surgical variability. Consistent phenotype confirmation via echocardiography across cohorts ensures that observations are robust and not driven by outliers. This reliability enables confident data sharing between discovery, preclinical, and translational teams.
What statistical analysis capabilities are required before implementing this model in a screening cascade?
Implementation requires statistical power analysis to account for the low yield of MOD phenotypes (~20%) and determine appropriate cohort sizes. Longitudinal data from echocardiography necessitate repeated measures ANOVA or mixed-effects models to assess changes over time. Predefined significance thresholds and correction for multiple comparisons are essential to avoid false positives in target validation screens.
